ANKMJ
Ankyra Medical Journal

Ankyra Medical Journal (AnkMJ), formerly known as the Journal of Translational and Practical Medicine, regularly publishes international quality issues in the field of Medicine in the light of current information.

eISSN: 3023-655X
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Online Manuscript System

Index
Original Article
Significance of soluble CD40 and CD40 ligand levels in childhood acute lymphoblastic leukemia patients
Abstract
Aim: Acute lymphoblastic leukemia (ALL) is the most prevalent malignant disorder in childhood. CD40 is a member of the tumor necrosis factor (TNF) receptor family. Soluble CD40 (sCD40) was previously found to be associated with poor prognosis in adult patients with hematologic malignancies such as acute myeloid leukemia (AML) and multiple myeloma. Experience in children, however, is rather limited. The present study aimed to investigate the significance of sCD40 and sCD40 ligand in children with ALL. Material and Method: This study recruited 44 children treated at Erciyes University , Division of Pediatric Hematology & Oncology between February 2008 and February 2010. We investigated the relationship between sCD40/sCD40 ligand at the diagnosis and remission during continuation phase with the prognosis of children with ALL. W e also considered the data on treatment response, relapse, and outcome. Results: The participating patients (20 girls and 25 boys) were between 22 months-18 years (mean 7.6±4.6 years) and had leukocytes at diagnosis between 870-741,660/mm3 (median 15,150/mm3). Thirty-five patients were diagnosed with B, whereas nine were diagnosed with T phenotype. In this cohort, 13 patients were classified in the standard-risk (SR) group, 20 patients were put in the intermediate-risk (IR) group, and 11 patients were categorized in the (HR) group according to the Turkish Acute Lymphoblastic Leukemia Berlin Frankfurt Munich (TR-ALL BFM) protocol. The serum levels of CD40/CD40 ligand at diagnosis were 22.41±9.91 ng/ml and 15.17±5.49 ng/ml, respectively, whereas these levels at remission were 0.22±0.38 ng/ml and 1.04±0.51 ng/ml, respectively. We detected significant changes in CD40 and CD40 ligand levels (p=0.008 and p<0.005, respectively) and early response on the 8th day. Although not significantly correlated with sCD40, the final outcome had a significant relationship with early response detected on the 8th day of treatment. We found the cut-off value of sCD40 to be 28.15 ng/dL in our cohort. The effect of sCD40 on event-free survival was clinically significant, but it did not yield statistical significance. Conclusion: Overall, our findings suggest that sCD40 is measured as increased at diagnosis of childhood ALL. On the basis of its physiological effect, sCD40 may have a role in modulating antitumor response in pediatric ALL and be a useful prognostic marker.

Keywords : Acute lymphoblastic leukemia, child, CD40, CD40 ligand, prognosis

Download Article


1. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol 2011; 29: 551-65.
2. Volejnikova J, Jarosova M, Pospisilova D, et al. Treatment and prognosis of childhood acute lymphoblastic leukemia on protocols ALL-BFM 90, 95 and ALL IC-BFM 2002: a retrospective single-center study from Olomouc, Czech Republic. Neoplasma 2016; 63: 456-61.
3. Kutluk T. Cocukluk cağı kanserlerin epidemiolojisi. Klinik Gelişim 2007; 20: 5-12.
4. Patıroğlu T, Karakükçü M, Kezer HM, Özdemir MA. Çocukluk çağı lösemi tedavisinde kemoradyoterapinin endokrin komplikasyonları. Erciyes Tıp Derg 2007; 29: 439-43.
5. Ünal E, Çalışkan Ü, Köksal Y. Çocukluk çağı akut lösemi ve hodgkin-dışı lenfoma hastalarında sistatin-c’nin nefrotoksisiteyi değerlendirmedeki önemi. UHOD 2009; 2: 68-74.
6. Patiroglu T, Unal E, Karakukcu M, et al. Multiple fungal brain abscesses in a child with acute lymphoblastic leukemia.Mycopathologia 2012; 174: 505-9.
7. Torun YA, Patiroglu T, Ozdemir MA, Ozkul Y, Ekici A, Karakukcu M. Inherited prothrombotic risk factors in Turkish children with acute lymphoblastic leukemia: significance of concomitant genetic mutation. Clin Appl Thromb Hemost 2012; 18: 218-21.
8. Chatzigeorgiou A, Lyberi M, Chatzilymperis G, Nezos A, Kamper E. CD40/CD40L signaling and its implication in health and disease. Biofactors 2009; 35: 474-83.
9. Loskog AS, Eliopoulos AG. The Janus faces of CD40 in cancer. Semin Immunol 2009; 21: 301-7.
10. Bereznaya NM, Chekhun VF. Expression of CD40 and CD40L on tumor cells: the role of their interaction and new approach to immunotherapy. Exp Oncol 2007; 29: 2-12.
11. Luqman M, Klabunde S, Lin K, et al. The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. Blood 2008112: 711-20.
12. Hock BD, McKenzie JL, Patton NW, et al. Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies. Cancer 2006; 106: 2148-57.
13. Stary J, Zimmermann M, Campbell M, et al. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002.
14. Hamurcu Z, Dönmez-Altuntas H, Patiroglu T. Basal level micronucleus frequency in stimulated lymphocytes of untreated patients with leukemia. Cancer Genet Cytogenet 2008; 180: 140-4.
15. Akcakus M, Patiroglu T, Deniz K, Cetin N, Ozdemir MA, Kala M. Congenital acute lymphoblastic leukemia: report of a case with leukemia cutis. Clin Pediatr (Phila) 2004; 43: 487-90.
16. Patıroglu T. A relationship between aneuploidy and prognosis in children with acute lymphoblastic leukemia. UHOD 2001,11: 148-53.
17. Ozdemir MA, Karakukcu M, Patiroglu T, Torun YA, Kose M. Management of hyperleukocytosis and prevention of tumor lysis syndrome with low-dose prednisone continuous infusion in children with acute lymphoblastic leukemia. Acta Haematol 2009; 121: 56-62.
18. Möricke A, Reiter A, Zimmermann M, et al. German-Austrian-Swiss ALL-BFM Study Group. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95.
19. Tong AW , Papayoti MH, Netto G, et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin Cancer Res 2001; 7: 691-703.
20. Baxendale AJ, Dawson CW, Stewart SE, et al. Constitutive activation of the CD40 pathway promotes cell transformation and neoplastic growth. Oncogene 2005; 24: 7913-23.
21. Tai YT , Podar K, Mitsiades N, et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3- kinase/AKT/NF-kappa B signaling. Blood 2003; 101: 2762-9.
22. Chiodoni C, Iezzi M, Guiducci C, et al. Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med 2006; 203: 2441-50.
23. Vanichakarn P, Blair P, Wu C, Freedman JE, Chakrabarti S. Neutrophil CD40 enhances platelet-mediated inflammation. Thromb Res 2008; 122: 346-58.
24. Cantwell M, Hua T, Pappas J, Kipps TJ. Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med 1997; 3: 984-9.
25. Skibola CF, Nieters A, Bracci PM, et al. A functional TNFRSF5 gene variant is associated with risk of lymphoma. Blood 2008; 111: 4348-54.
26. Brouwer RE, Hoefnagel J, Borger van Der Burg B, et al. Expression of co-stimulatory and adhesion molecules and chemokine or apoptosis receptors on acute myeloid leukaemia: high CD40 and CD11a expression correlates with poor prognosis. Br J Haematol 2001; 115: 298-308.
27. Gruss HJ, Herrmann F, Gattei V, Gloghini A, Pinto A, Carbone A. CD40/CD40 ligand interactions in normal, reactive and malignant lympho-hematopoietic tissues. Leuk Lymphoma 1997; 24: 393-422.
28. Blair PJ, Riley JL, Harlan DM, et al. CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. J Exp Med 2000; 191: 651-60.
29. Yüksel-Soycan L, Aydoğan G, Tanyeli A, et al. BFM-TR ALL 2000: First Turkish Multicentric study in the treatment of pediatric acute lymphoblastic leukemia. Pediatric Blood Cancer 2006; 47: 426-7.
Article available in :
Volume 1, Issue 2, 2022
Page : 49-56
https://doi.org/10.51271/JTPM-0012
Article Information
Received : 14 Ağu 2022
Accepted : 20 Eyl 2022
Published : 30 Eyl 2022
Corresponding Author :

Ekrem Ünal: Department of Pediatric Hematology, Medical Point Gaziantep Hospital, Gaziantep, Türkiye

[email protected]
Citation : Gök V , Özcan A, Yılmaz E, et al. Significance of soluble CD40 and CD40 ligand levels in childhood acute lymphoblastic leukemia patients. J Transl Pract Med 2022; 1(2): 49-56.

Read: 492
Download : 521
Cited: 0
_Footer